Literature DB >> 27067725

Understanding the cellular roles of Fyn-related kinase (FRK): implications in cancer biology.

Raghuveera Kumar Goel1, Kiven Erique Lukong2.   

Abstract

The non-receptor tyrosine kinase Fyn-related kinase (FRK) is a member of the BRK family kinases (BFKs) and is distantly related to the Src family kinases (SFKs). FRK was first discovered in 1993, and studies pursued thereafter attributed a potential tumour-suppressive function to the enzyme. In recent years, however, further functional characterization of the tyrosine kinase in diverse cancer types suggests that FRK may potentially play an oncogenic role as well. Specifically, while ectopic expression of FRK suppresses cell proliferation and migration in breast and brain cancers, knockdown or catalytic inhibition of FRK suppresses these cellular processes in pancreatic and liver cancer. Such functional paradox is therefore evidently exhibited in a tissue-specific context. This review sheds light on the recent developments emerged from investigations on FRK which include: (a) a review of the expression pattern of the protein in mammalian cells/tissues, (b) underlying genomic perturbations and (c) a mechanistic function of the enzyme across different cellular environments. Given its functional heterogeneity observed across different cancers, we also discuss the therapeutic significance of FRK.

Entities:  

Keywords:  BFKs; BRK; Breast cancer; FRK; Fyn; Oncogene; PTEN; PTK5; Rak; SRMS; Src; Tumour suppressor; Tyrosine kinase

Mesh:

Substances:

Year:  2016        PMID: 27067725     DOI: 10.1007/s10555-016-9623-3

Source DB:  PubMed          Journal:  Cancer Metastasis Rev        ISSN: 0167-7659            Impact factor:   9.264


  18 in total

1.  Phosphoproteomics Analysis Identifies Novel Candidate Substrates of the Nonreceptor Tyrosine Kinase, Src-related Kinase Lacking C-terminal Regulatory Tyrosine and N-terminal Myristoylation Sites (SRMS).

Authors:  Raghuveera Kumar Goel; Marta Paczkowska; Jüri Reimand; Scott Napper; Kiven Erique Lukong
Journal:  Mol Cell Proteomics       Date:  2018-03-01       Impact factor: 5.911

2.  Development and Validation of a Novel 8 Immune Gene Prognostic Signature Based on the Immune Expression Profile for Hepatocellular Carcinoma.

Authors:  Dafeng Xu; Yu Wang; Kailun Zhou; Jincai Wu; Zhensheng Zhang; Jiachao Zhang; Zhiwei Yu; Luzheng Liu; Xiangmei Liu; Bidan Li; Jinfang Zheng
Journal:  Onco Targets Ther       Date:  2020-08-14       Impact factor: 4.147

3.  Newly identified LMO3-BORCS5 fusion oncogene in Ewing sarcoma at relapse is a driver of tumor progression.

Authors:  Célia Dupain; Céline Gracia; Anne C Harttrampf; Julie Rivière; Birgit Geoerger; Liliane Massaad-Massade
Journal:  Oncogene       Date:  2019-09-05       Impact factor: 9.867

4.  Repression of Fyn-related kinase in breast cancer cells is associated with promoter site-specific CpG methylation.

Authors:  Edward T Bagu; Sayem Miah; Chenlu Dai; Travis Spriggs; Yetunde Ogunbolude; Erika Beaton; Michelle Sanders; Raghuveera K Goel; Keith Bonham; Kiven E Lukong
Journal:  Oncotarget       Date:  2017-02-14

5.  A novel chalcone derivative suppresses melanoma cell growth through targeting Fyn/Stat3 pathway.

Authors:  Ling Tang; Jing Long; Keke Li; Xu Zhang; Xiang Chen; Cong Peng
Journal:  Cancer Cell Int       Date:  2020-06-18       Impact factor: 5.722

6.  The nonreceptor tyrosine kinase SRMS inhibits autophagy and promotes tumor growth by phosphorylating the scaffolding protein FKBP51.

Authors:  Jung Mi Park; Seung Wook Yang; Wei Zhuang; Asim K Bera; Yan Liu; Deepak Gurbani; Sergei J von Hoyningen-Huene; Sadie Miki Sakurada; Haiyun Gan; Shondra M Pruett-Miller; Kenneth D Westover; Malia B Potts
Journal:  PLoS Biol       Date:  2021-06-02       Impact factor: 8.029

7.  FRK inhibits breast cancer cell migration and invasion by suppressing epithelial-mesenchymal transition.

Authors:  Yetunde Ogunbolude; Chenlu Dai; Edward T Bagu; Raghuveera Kumar Goel; Sayem Miah; Joshua MacAusland-Berg; Chi Ying Ng; Rajni Chibbar; Scott Napper; Leda Raptis; Frederick Vizeacoumar; Franco Vizeacoumar; Keith Bonham; Kiven Erique Lukong
Journal:  Oncotarget       Date:  2017-12-06

8.  Targeting focal adhesion kinase overcomes erlotinib resistance in smoke induced lung cancer by altering phosphorylation of epidermal growth factor receptor.

Authors:  Hitendra S Solanki; Remya Raja; Alex Zhavoronkov; Ivan V Ozerov; Artem V Artemov; Jayshree Advani; Aneesha Radhakrishnan; Niraj Babu; Vinuth N Puttamallesh; Nazia Syed; Vishalakshi Nanjappa; Tejaswini Subbannayya; Nandini A Sahasrabuddhe; Arun H Patil; T S Keshava Prasad; Daria Gaykalova; Xiaofei Chang; Rachana Sathyendran; Premendu Prakash Mathur; Annapoorni Rangarajan; David Sidransky; Akhilesh Pandey; Evgeny Izumchenko; Harsha Gowda; Aditi Chatterjee
Journal:  Oncoscience       Date:  2018-02-23

9.  Targetable fusions of the FRK tyrosine kinase in ALK-negative anaplastic large cell lymphoma.

Authors:  G Hu; S Dasari; Y W Asmann; P T Greipp; R A Knudson; H K Benson; Y Li; B W Eckloff; J Jen; B K Link; L Jiang; J S Sidhu; L E Wellik; T E Witzig; N N Bennani; J R Cerhan; R L Boddicker; A L Feldman
Journal:  Leukemia       Date:  2017-10-13       Impact factor: 11.528

10.  Global phosphoproteomic analysis identifies SRMS-regulated secondary signaling intermediates.

Authors:  Raghuveera Kumar Goel; Mona Meyer; Marta Paczkowska; Jüri Reimand; Frederick Vizeacoumar; Franco Vizeacoumar; TuKiet T Lam; Kiven Erique Lukong
Journal:  Proteome Sci       Date:  2018-08-18       Impact factor: 2.480

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.